The effects of different doses of atorvastatin on plasma endothelin-1 levels in type 2 diabetic patients with dyslipidemia

Experimental Biology and Medicine

Volumn 231, Issue 6, 2006, Pages 1010-1015

  Lam, Hing Chung ^a,b   Chu, Chih Hsun ^a,b   Wei, Mei Chih ^a   Keng, Hsiu Man ^a   Lu, Chih Chen ^a,b   Sun, Chun Chin ^a   Lee, Jenn Kuen ^a,b   Chuang, Ming Ju ^a   Wang, Mei Chun ^a   Tai, Ming Hong ^a  

^a KAOHSIUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

Atorvastatin; CRP; Dyslipidemia; Endothelin 1; Type 2 diabetes

Indexed keywords

ATORVASTATIN; C REACTIVE PROTEIN; CHOLESTEROL; ENDOTHELIN 1; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DOSE RESPONSE; DRUG INHIBITION; DRUG MECHANISM; DRUG TOLERANCE; DYSLIPIDEMIA; FEMALE; HUMAN; MALE; RANDOMIZED CONTROLLED TRIAL;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHOLESTEROL; CHOLESTEROL, LDL; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DYSLIPIDEMIAS; ENDOTHELIN-1; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; PYRROLES;

EID: 33744910581     PISSN: 15353702     EISSN: 15353699     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (23)

1. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 16:434-444, 1993.
2. Syvanne M, Taskinen M. Lipids and lipoproteins as coronary risk factors in non-insulin-dependant diabetes mellitus. Lancet 350(suppl 1):S120-S123, 1997.
3. Takahashi K, Ghatei MA, Lam HC, O'Halloran DJ, Bloom SR. Elevated plasma endothelin in patients with diabetes mellitus. Diabetologia 33:306-310, 1990.
4. Lam HC. Review: role of endothelin in diabetic vascular complications. Endocrine 14:277-284, 2001.
5. Lam HC, Lee JK, Lu CC, Chu CH, Chuang MJ, Wang MC. Role of endothelin in diabetic retinopathy. Curr Vasc Pharmacol 1:243-250, 2003.
6. Collins R, Armitage J, Parish S, Sleigh P, Peto R, Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 361:2005-2016, 2003.
7. Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J, ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 361:1149-1158, 2003.
8. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, Thomason MJ, Mackness MI, Charlton-Menys V, Fuller JH, CARDS investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomized placebo-controlled trial. Lancet 364:685-696, 2004.
9. Hernandez-Perera O, Perez-Sala D, Navarro-Antolin J, Sanchez-Pascuala R, Hernandez G, Diaz C, Lamas S. Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin- 1 and endothelial nitric oxide synthase in vascular endothelial cells. J Clin Invest 101:2711-2719, 1998.
10. Nakamura T, Ushiyama C, Hirokawa K, Osada S, Shimada N, Koide H. Effect of cerivastatin on urinary albumin excretion and plasma endothelin-1 concentration in type 2 diabetes patients with microalbuminuria and dyslipidemia. Am J Nephrol 21:449-454, 2001.
11. Economides PA, Caselli A, Tiani E, Khaodhiar L, Horton ES, Veves A. The effects of atorvastatin on endothelial function in diabetic patients and subjects at risk for type 2 diabetes. J Clin Endocrinol Metab 89:740-747, 2004.
12. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low density lipoprotein cholesterol in plasma without the use of the preparative ultracentrifuge. Clin Chem 18:499-502, 1972.
13. Schrott H, Fereshetian AG, Knopp RH, Bays H, Jones PH, Littlejohn TW 3rd, McLain R, Black DM. A multicenter, placebo-controlled, dose-ranging study of atorvastatin. J Cardiovasc Pharmacol Ther 3:119-124, 1998.
14. Wierzbicki AS, Mikhailidis DP. Dose-response effects of atorvastatin and simvastatin on high-density lipoprotein cholesterol in hypercholesterolaemic patients: a review of five comparative studies. Int J Cardiol 84:53-57, 2002.
15. Diabetes Atorvastatin Lipid Intervention (DALI) Study Group. The effect of aggressive versus standard lipid lowering by atorvastatin on diabetic dyslipidemia: the DALI study: a double-blind, randomized, placebo-controlled trial in patients with type 2 diabetes and diabetic dyslipidemia. Diabetes Care 24:1335-1341, 2001.
16. Barton M, Kiowski W. The therapeutic potential of endothelin receptor antagonists in cardiovascular disease. Curr Hypertens Rep 3:322-330, 2001.
17. Torzewski M, Rist C, Mortensen RF, Zwaka TP, Bienek M, Waltenberger J, Koenig W, Schmitz G, Hombach V, Torzewski J. C-reactive protein in the arterial intima: role of C-reactive protein receptor-dependent monocyte recruitment in atherogenesis. Arterioscler Thromb Vasc Biol 20:2094-2099, 2000.
18. Ridker PM, Glynn RJ, Hennekens CH. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation 97:2007-2011, 1998.
19. Albert MA, Danielson E, Rifai N, Ridker PM. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA 286:64-70, 2001.
20. Lam HC, Lo GH, Lee JK, Lu CC, Chu CH, Sun CC, Chuang MJ, Wang MC. Salivary immunoreactive endothelin in patients with upper gastrointestinal diseases. J Cardiovasc Pharmacol 44(Suppl 1):S413-S417, 2004.
21. Haak T, Jungmann E, Raab C, Usadel KH. Elevated endothelin-1 levels after cigarette smoking. Metabolism 43:267-269, 1994.
22. Bazzano LA, He J, Muntner P, Vupputuri S, Whelton PK. Relationship between cigarette smoking and novel risk factors for cardiovascular disease in the United States. Ann Intern Med 138:891-897, 2003.
23. van Venrooij FV, van de Ree MA, Bots ML, Stolk RP, Huisman MV, Banga JD. Aggressive lipid lowering does not improve endothelial function in type 2 diabetes: the Diabetes Atorvastatin Lipid Intervention (DALI) Study: a randomized, double-blind, placebo-controlled trial. Diabetes Care 25:1211-1216, 2002.